論文

国際誌
2021年12月

Osteosarcoma Patient-derived Orthotopic Xenograft (PDOX) Models Used to Identify Novel and Effective Therapeutics: A Review.

Anticancer research
  • Takashi Higuchi
  • ,
  • Kentaro Igarashi
  • ,
  • Norio Yamamoto
  • ,
  • Katsuhiro Hayashi
  • ,
  • Hiroaki Kimura
  • ,
  • Shinji Miwa
  • ,
  • Michael Bouvet
  • ,
  • Hiroyuki Tsuchiya
  • ,
  • Robert M Hoffman

41
12
開始ページ
5865
終了ページ
5871
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.21873/anticanres.15406

BACKGROUND/AIM: Recurrent osteosarcoma is recalcitrant with poor response rates to first-line chemotherapy due to heterogeneity and metastatic potential. This disease requires novel drug discovery and precision treatment. MATERIALS AND METHODS: The osteosarcoma patient-derived orthotopic xenograft (PDOX) mouse model mimics the clinical disease and has identified effective clinically-approved drugs and experimental agents, especially drug combinations, that hold much clinical promise. RESULTS: Effective treatment for drug-resistant osteosarcoma includes regorafenib, as monotherapy, and temozolomide-irinotecan, trabectedin-irinotecan, sorafenib-everolimus, sorafenib-palbociclib, and olaratumab-doxorubicin-cisplatinum, as combinations. CONCLUSION: The PDOX model can be used to improve the outcome of osteosarcoma patients, including individualized, precision therapy.

リンク情報
DOI
https://doi.org/10.21873/anticanres.15406
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/34848441
ID情報
  • DOI : 10.21873/anticanres.15406
  • PubMed ID : 34848441

エクスポート
BibTeX RIS